


Ofatumumab

Printed from <https://www.cancerquest.org/node/6368> on 04/26/2026



Brand name: Arzerra

FDA approval: Yes

[Enlace del fabricante](#)

Usage:

Arzerra is a monoclonal antibody, which uses natural immune functions to fight cancer cells. Arzerra is typically used in conjunction with chemotherapy to fight chronic lymphocytic leukemia (CLL) in adults.¹

1 ARZERRA® (ofatumumab). (n.d.). Retrieved June 22, 2017, from <https://www.us.arzerra.com/?site=43700015041483999&source=01030>

Mechanism:

Ofatumumab, which is used in the treatment of CCL, is a human monoclonal antibody to CD20, which is a cell surface antigen found on pre-B and mature B lymphocytes. Ofatumumab also has vast immunosuppressive activity, which means it can have poor reactions in patients with Hepatitis B and HBV.¹

The diagram below shows the 3D model of Ofatumumab.

1 Ofatumumab. (n.d.). Retrieved June 22, 2017, from <https://pubchem.ncbi.nlm.nih.gov/compound/6918251#section=Top>

Side effects:

Arzerra can cause a side effect called infusion reaction, which requires stoppage of treatment and immediate attention. Symptoms of infusion reaction include: fever, chills, rash, hives, chest pain, back pain, stomach pain, swelling dizziness and cold-like symptoms. More common side effects of Arzerra include: low white blood cell count, pneumonia, fever, cough, diarrhea, low red blood cell count, tiredness, shortness of breath, rash, nausea and upper respiratory problems.¹

1 ARZERRA® (ofatumumab). (n.d.). Retrieved June 22, 2017, from <https://www.us.arzerra.com/?site=43700015041483999&source=01030>

Contraindications:

Tell your doctor if you have Hepatitis B or are a carrier for HBV, as Arzerra can cause infections to worsen. Arzerra in conjunction with HBV can also cause severe liver problems and possible death. During infusions patients should be aware of infusion reaction occurring, which has symptoms that include: fever, chills, rash, hives, chest pain, back pain, stomach pain, swelling dizziness and cold-like symptoms.¹

1 ARZERRA® (ofatumumab). (n.d.). Retrieved June 22, 2017, from <https://www.us.arzerra.com/?site=43700015041483999&source=01030>

